The Peel with Turner Novak How to Build a Biotech with Celine Halioua at Loyal
May 2, 2024
Celine Halioua, CEO of Loyal, discusses developing longevity drugs for dogs and potentially humans. Topics include FDA approval process, differences between biotech and software startups, mistakes as a founder, growth rate in hiring, and starting with dogs for drug development.
AI Snips
Chapters
Transcript
Episode notes
Preventative Aging Beats Immortality
- Loyal targets preventative aging medicine that reduces multiple age-related diseases at once rather than chasing immortality.
- The goal is to extend healthy, high-quality years (health-span) which then extends lifespan as a secondary outcome.
Approval Creates A Longevity Ecosystem
- The first approved lifespan/health-span drug will unlock many follow-on therapies and rapid innovation.
- Approval acts like a market signal that converts latent demand into investment and product iterations.
Protect The Field By Managing Risk
- Treat novel, high-profile failures as industry risks and manage credibility accordingly.
- Build progress deliberately so your failure won't set back the entire nascent field.